scholarly journals Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β-blockers

2018 ◽  
Vol 41 (3) ◽  
pp. 406-412 ◽  
Author(s):  
Phillip H. Lam ◽  
Poonam Bhyan ◽  
Cherinne Arundel ◽  
Daniel J. Dooley ◽  
Helen M. Sheriff ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Lower Risk ◽  
Older Patients ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
Β Blockers

scholarly journals Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction

2019 ◽  
Vol 132 (1) ◽  
pp. 71-80.e1 ◽  
Author(s):  
Essraa Bayoumi ◽  
Phillip H. Lam ◽  
Daniel J. Dooley ◽  
Steven Singh ◽  
Charles Faselis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Older Patients ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure

Implementation of Guideline-Recommended Therapies for Patients With Heart Failure and Reduced Ejection Fraction: A Regional Arab Middle East Experience

Angiology ◽  
2020 ◽  
Vol 71 (5) ◽  
pp. 431-437
Author(s):  
Mohammad Zubaid ◽  
Wafa Rashed ◽  
Mustafa Ridha ◽  
Nooshin Bazargani ◽  
Adel Hamad ◽  
...  
Keyword(s):  
Heart Failure ◽  
Middle East ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Angiotensin Receptor ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
Β Blocker ◽  
Β Blockers

We describe the characteristics of ambulatory patients with heart failure with reduced ejection fraction (HFrEF) in the Gulf region (Middle East) and the implementation of guideline-recommended treatments. We included 2427 HFrEF outpatients (mean age 59 ± 13 years, 75% males and median left ventricular ejection fraction [LVEF] of 30%). A high proportion of patients received guideline-recommended medications (angiotensin-converting enzyme inhibitor [ACEI]/angiotensin receptor blocker [ARB]/angiotensin receptor-neprilysin inhibitor [ARNI] 87%, β-blocker 91%, mineralocorticoid antagonist [MRA] 64%). However, only a minority of patients received guideline-recommended target doses (ACEI/ARB/ARNI 13%, β-blocker 27%, and MRA 4.4%). Old age was a significant independent predictor for not prescribing treatment ( P < .001 for ACEI/ARB/ARNI and MRA; and P = .002 for β-blockers). Other independent predictors were chronic kidney disease (for both ACEI/ARB/ARNI and MRA, P < .001) and higher LVEF ( P = .014 for β-blockers and P < .001 for MRA). Patients with HFrEF managed by heart failure specialists more often received recommended target doses of ACEI/ARB/ARNI (40% vs 11%, P < .001) and β-blockers (56% vs 26%, P < .001) compared to those treated by general cardiologists. Although the majority of our patients with HFrEF received guideline-recommended medications, the doses they were prescribed were suboptimal. Understanding the reasons behind this is important for improved practice.

PREDICTORS OF 6-MONTH HEART FAILURE READMISSION AND DEATH IN OLDER PATIENTS WITH HEART FAILURE WITH PRESERVED VERSUS REDUCED EJECTION FRACTION

2018 ◽  
Vol 71 (11) ◽  
pp. A856
Author(s):  
Cherinne Arundel ◽  
Helen Sheriff ◽  
Fahad K. Lodhi ◽  
Charity Morgan ◽  
Steven Singh ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Older Patients ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure

scholarly journals Beta Blockers Up-Titration in Patients with Heart Failure Reduced Ejection Fraction and Cardiac Resynchronization Therapy, a Single Center Study

2019 ◽  
Vol 7 (6) ◽  
pp. 71
Author(s):  
Daniele Masarone ◽  
Marina Verrengia ◽  
Ernesto Ammendola ◽  
Rita Gravino ◽  
Fabio Valente ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Cardiac Resynchronization Therapy ◽  
Cardiac Resynchronization ◽  
Resynchronization Therapy ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
Β Blockers ◽  
Group 2 ◽  
Group 1

Clinical trials have shown the benefits of β-blockers therapy in patients with heart failure reduced ejection fraction. These benefits include improved survival and a reduced need for hospitalization. Cardiac resynchronization therapy has emerged as an essential device-based therapy for symptomatic patients with heart failure reduced ejection fraction despite optimal pharmacologic treatment. The extent to which β-blockers are being utilized in patients receiving cardiac resynchronization therapy is not well known. In this study, we evaluate the possibility of increasing β-blockers doses in an unselected cohort of heart failure reduced ejection patients after cardiac resynchronization therapy capable defibrillator system implantation and the correlation between β-blockers treatments and clinical outcome. Methods and results: Patients with heart failure reduced ejection fraction in β-blockers therapy that underwent cardiac resynchronization therapy capable defibrillator system implantation between July 2008, and December 2016 were enrolled in the study. The β-blockers dose was determined at the time of discharge and during follow-up. Cardiovascular mortality, hospitalization for worsening heart failure or arrhythmic storm and appropriate intervention of the device, were recorded. The study cohort included 480 patients, 289 patients (60.3%) had β-blockers doses equal to the dose before CRT (Group 1), 191 patients (39.7%) had higher β-blockers doses than those before the CRT implant (Group 2). Comparing the two groups, Group 2 have lower cardiovascular mortality, heart failure-related hospitalization, and arrhythmic events than Group 1. Conclusion: After initiating CRT, β-blockers could be safely up-titrated at higher doses with the reduction in mortality, heart failure-related hospitalization, and arrhythmic events.

Sign in / Sign up

Export Citation Format

Share Document